Draft:LAPaL

Review waiting, please be patient. This may take 3 months or more, since drafts are reviewed in no specific order. There are 2,841 pending submissions waiting for review. If the submission is accepted, then this page will be moved into the article space. If the submission is declined, then the reason will be posted here. In the meantime, you can continue to improve this submission by editing normally. Where to get help If you need help editing or submitting your draft, please ask us a question at the AfC Help Desk or get live help from experienced editors. These venues are only for help with editing and the submission process, not to get reviews. If you need feedback on your draft, or if the review is taking a lot of time, you can try asking for help on the talk page of a relevant WikiProject. Some WikiProjects are more active than others so a speedy reply is not guaranteed. How to improve a draft Wikipedia:Contributing to Wikipedia – a basic overview on how to edit Wikipedia. Help:Wikitext – how to use the markup Help:Referencing for beginners – how to include references Wikipedia:Article development – how to develop your article Wikipedia:Writing better articles – how to improve your article Wikipedia:Verifiability – make sure your article includes reliable third-party sources You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Add tags to your draft Editor resources Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL Easy tools: Citation bot (help) | Advanced: Fix bare URLs Reviewer tools Instructions · What links here · LAPaL (talk: + · bio) · (log) · Copyvios report · reFill · Citation Bot · (Search: Google, Bing, Wikipedia) · Submitted 4 days ago by Prajithkanna (talk: D · +) · Last edited 3 days ago by Citation bot

Submission declined on 10 July 2024 by MicrobiologyMarcus (talk). This submission is not adequately supported by reliable sources. Reliable sources are required so that information can be verified. If you need help with referencing, please see Referencing for beginners and Citing sources. This submission appears to read more like an advertisement than an entry in an encyclopedia. Encyclopedia articles need to be written from a neutral point of view, and should refer to a range of independent, reliable, published sources, not just to materials produced by the creator of the subject being discussed. This is important so that the article can meet Wikipedia's verifiability policy and the notability of the subject can be established. If you still feel that this subject is worthy of inclusion in Wikipedia, please rewrite your submission to comply with these policies. If you would like to continue working on the submission, click on the "Edit" tab at the top of the window. If you have not resolved the issues listed above, your draft will be declined again and potentially deleted. If you need extra help, please ask us a question at the AfC Help Desk or get live help from experienced editors. Please do not remove reviewer comments or this notice until the submission is accepted. Where to get help If you need help editing or submitting your draft, please ask us a question at the AfC Help Desk or get live help from experienced editors. These venues are only for help with editing and the submission process, not to get reviews. If you need feedback on your draft, or if the review is taking a lot of time, you can try asking for help on the talk page of a relevant WikiProject. Some WikiProjects are more active than others so a speedy reply is not guaranteed. How to improve a draft Wikipedia:Contributing to Wikipedia – a basic overview on how to edit Wikipedia. Help:Wikitext – how to use the markup Help:Referencing for beginners – how to include references Wikipedia:Article development – how to develop your article Wikipedia:Writing better articles – how to improve your article Wikipedia:Verifiability – make sure your article includes reliable third-party sources You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Add tags to your draft Editor resources Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL Easy tools: Citation bot (help) | Advanced: Fix bare URLs Declined by MicrobiologyMarcus 10 days ago. Last edited by Citation bot 3 days ago. Reviewer: Inform author. This draft has been resubmitted and is currently awaiting re-review.

Submission declined on 5 July 2024 by MicrobiologyMarcus (talk). This submission is not adequately supported by reliable sources. Reliable sources are required so that information can be verified. If you need help with referencing, please see Referencing for beginners and Citing sources. Declined by MicrobiologyMarcus 14 days ago.

Submission declined on 1 July 2024 by Jamiebuba (talk). This draft's references do not show that the subject qualifies for a Wikipedia article. In summary, the draft needs multiple published sources that are: in-depth (not just passing mentions about the subject) reliable secondary independent of the subject Make sure you add references that meet these criteria before resubmitting. Learn about mistakes to avoid when addressing this issue. If no additional references exist, the subject is not suitable for Wikipedia. Declined by Jamiebuba 19 days ago.

Submission declined on 1 July 2024 by Ae245 (talk). This submission is not adequately supported by reliable sources. Reliable sources are required so that information can be verified. If you need help with referencing, please see Referencing for beginners and Citing sources. This submission does not appear to be written in the formal tone expected of an encyclopedia article. Entries should be written from a neutral point of view, and should refer to a range of independent, reliable, published sources. Please rewrite your submission in a more encyclopedic format. Please make sure to avoid peacock terms that promote the subject. Declined by Ae245 19 days ago.

• Comment: Innapropriate inline WP:External links and full of promotional wording. microbiologyMarcus ^{[petri dish·growths]} 13:56, 10 July 2024 (UTC)

• Comment: See WP:REFB for understanding how to use WP:Inline citations. microbiologyMarcus ^{[petri dish·growths]} 16:08, 5 July 2024 (UTC)

The Long-Acting Therapeutics Patents and Licensing Database (LAPaL) is a publicly available database dedicated to providing comprehensive data on long-acting medicinal products and extended-release drug delivery technologies worldwide. This open-access, collaborative resource aims to facilitate partnerships in the long-acting therapeutics space and to improve access to these health interventions. LAPaL includes information on the main characteristics of the drugs and drug technologies and an overview of their intellectual property, clinical trials landscape as well as information on their national filings. With support from Unitaid, it was launched in 2021 by the Medicines Patent Pool ^[1]. Additional funding was received from the NIH through the LEAP program. LAPaL offers comprehensive and up-to-date information on the technical specifications, developmental progress, and intellectual property (IP) status of a selection of long-acting treatments to improve health outcomes in low- and middle-income nations. The primary interest of LAPaL is long-acting therapeutics ^[2]. These formulations of medicines elicit less frequent administration while maintaining safe and effective dosing to treat or prevent a set of conditions. Long-acting formulations are often an important alternative for health care providers, persons receiving the medications, and their caregivers. The potential benefits of long-acting therapeutics include enhanced adherence to the prescribed regimen, improved clinical efficacy, and in some instances, improved safety, and a decrease in the relapse rates ^[3]. LAPaL covers a wide array of health areas, including HIV, malaria, hepatitis, respiratory syncytial virus, mental health disorders, and other indications ^[4].

The main aim of the LAPaL database is to provide verified open-access information on pharmacological features and intellectual property status of a selection of long-acting therapeutics and their potential applications ^[1]. To utilize advanced algorithms and data sourcing mechanisms for accurate intellectual property information.

Long-acting platform technologies that are included in LAPaL elicit a sustained release or prolonged therapeutics activity of medicines. Their features are displayed, as well as information on their intellectual property landscape, and studied applications when these are in the public domain. The technology entries are initiated by the technology manufacturer, main sponsor, or LAPAL team. An overview of the various technologies features, including comparisons of the studied or approved routes of administration, therapeutic applications, as well as advancement in the clinical pipeline are showcased ^[4].

The database includes compounds with a prolonged half-life and a sustained release profile, with dosing schedules ranging from once a week to once a year. Alternatively, it includes compounds that are being studied, developed or approved for use in a long-acting eliciting formulation, at times, in combination with a long-acting platform ^[5]. Compounds are categorized into small molecules and biotherapeutics. Given the trend in clinical developments and the potential for global impact, the database is currently witnessing an increase in the biotherapeutics: small molecules entries ratio ^[6].

The LAPaL database contains global in-country regulatory approvals and globally registered clinical trials information on marketed and investigational long-acting therapeutics, serving as a reliable technical resource for communities living with or at risk of the conditions covered, healthcare professionals, innovators, researchers, manufacturers, government bodies, civil society and funders interested in prolonged and sustained-release therapeutics ^[5]. In the database, external users can register and propose additions to the database. There is a landscape created in the LAPaL website that allows users to toggle in the world map and identify individual LA drug approvals. This landscape illustrates the global regulatory in-country approvals, clinical trial details like mean age, gender, and other details ^{[4] [5]}.

• Comprehensive Listings: LAPaL provides comprehensive information on a range of long-acting compounds, technologies, and formulations, including their physico-chemical characteristics, mechanisms of action, intellectual property landscape, registered clinical trials, and regulatory approval status where applicable ^[7].
• Search and Filter Capabilities: The platform allows users to search for specific compounds or technologies using various filters such as therapeutic area, route of administration, targeted population, and frequency of administration. This functionality supports the retrieval of relevant information ^[1].
• Comparison tool: Similar to an online product comparator ^[8], LAPaL included a feature where users can see side-by-side selected long-acting therapeutics and compare their characteristics.
• User Interface: The database features a simple interface that facilitates navigation. Information is organized allowing users to find the required details.

• Patent and Licensing Information: The database also contains detailed information on patents relevant to long-acting therapeutics, including details on licensing deals and patent expiry dates. Users can access summaries of global patent statuses, classified by country income levels. ^[9]. Intellectual property data is curated by a team at MPP and supported by MedsPaL’s algorithms and data sourcing mechanisms ^{[10] [11][12] [13]}.
• Regular updates: New long-acting therapeutics entries, compounds, and technologies, new clinical trials, in-country approvals, and key clinical results are updated by a team of data curators at the University of Liverpool. Additional patents and changes in patent status are also monitored. The data curators of the University of Liverpool are responsible for the scientific content in the database ^[14].
• Educational Resources: The website also contains educational resources for professionals with varying levels of experience, such as a compilation of key scientific or institutional publications, and links to other organizations and projects if interested in the long-acting space ^[7].

LAPaL is a collaborative initiative funded by Unitaid and coordinated by the Medicines Patent Pool (MPP). It also receives funding from the National Institute of Health (NIH) through the Long-Acting/Extended Release Antiretroviral Research Resource Program (LEAP) and in partnership with the University of Liverpool and AIDS Vaccine Advocacy Coalition (AVAC)^[15]. Unitaid is a not-for-profit dedicated to making new health products available and affordable for people in low- and middle-income countries ^[16]. The LEAP program is dedicated to advancing antiretroviral research and development, particularly long-acting or extended-release treatments and prevention options, as these formulations elicit the maintenance of therapeutic drug levels over long periods^[17].